NEW YORK — People who are suffering from urinary or respiratory tract infections may face nearly double the risk of heart attacks and strokes than obesity, researchers have warned.
The study — led by a researcher of Indian origin — found that if the frequency of these common infections causing hospitalisation continues for a longer period it may even lead to death.
Patients diagnosed with any one of these common infections were three times more likely to die than those without prior infection after developing heart disease, and almost twice as likely to die if they had a stroke.
“Our figures suggest that those who are admitted to hospital with a respiratory or urinary tract infection are 40 per cent more likely to suffer a subsequent heart attack, and 2.5 times more likely to have a stroke, than patients who have had no such infection, and are considerably less likely to survive from these conditions,” Rahul Potluri, researcher at Britain’s Aston University, said in a statement.
The effects of the common infections were of similar magnitude among the people suffering from diabetes, hypertension, and cholesterol, researchers said.
“It is notable that infection appears to confer as much, if not more, of a risk for future heart disease and stroke as very well established risk factors such as high blood pressure and diabetes,” Potluri added.
Researchers conducted the study over 34,027 patients who had been admitted with a urinary or respiratory tract infection with an age and sex-matched control group without infection.
Factors such as age, gender, ethnicity, obesity and tobacco use, as well as medical conditions including excess cholesterol, high blood pressure, diabetes and kidney disease, heart failure and atrial fibrillation were also taken into account.Follow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost